Research and Markets: PharmaPoint: HIV - Brazil Drug Forecast and Market Analysis to 2022

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lp5dhv/pharmapoint_hiv) has announced the addition of GlobalData's new report "PharmaPoint: HIV - Brazil Drug Forecast and Market Analysis to 2022" to their offering.

“PharmaPoint: HIV - Brazil Drug Forecast and Market Analysis to 2022”

Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Unlike the seven major markets, the market in Brazil mostly represents revenues generated from the sale of generics. It is interesting to note that the absence of STRs and FDCs, such as Gilead's Truvada or ViiV's Epzicom, is because of the high cost of these therapies. GlobalData estimates that ViiV will launch its pipeline candidate, 572-Trii, as a novel STR in an attempt to break into this market. The NRTI class is represented mainly by generic Combivir, followed by generic lamivudine and tenofovir.

Scope

- Overview of HIV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in Brazil from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting Brazil HIV market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for HIV

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2012-2022 in Brazil

For more information visit http://www.researchandmarkets.com/research/lp5dhv/pharmapoint_hiv

Source: GlobalData